Rez serves as head of the Merck European Innovation Hub in London, leading business development and licensing activities, with a focus on early-stage therapeutics, i.e. pre-clinical to proof-of-concept, and novel technology platforms.
He is also a partner in the MRL Venture Fund with responsibility for European investments. The European Innovation Hub offers a range of partnering constructs to match the interests of European innovators: collaborations, licensing and independent venture investments.
Previously, Rez was a partner with the corporate venture capital arm of Partners HealthCare, a large academic medical center and Harvard Medical School affiliate, based in Boston, US. In this role, he led investments and had Board responsibility for a number of therapeutics and technology platform companies, spanning infectious disease, oncology, neurology, inflammation and genome editing. Prior to this, he was a founding member of a US-based product development company, BioMed Valley Discoveries, that in-licensed and advanced a number of oncology assets into clinical trials. He also had management roles of increasing responsibility at Novartis, based in the US, initially in the diabetes and metabolism group, and then in an internal incubator with a mandate to develop programs outside the core disease areas. Earlier in his career, he led research at Xcellsyz Ltd, a venture-backed start up in the UK. Rez holds a B.Sc. and Ph.D. from Newcastle University, UK.